- Home
- INKT
as 02-21-2025 4:00pm EST
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 36.7M | IPO Year: | 2021 |
| Target Price: | $6.50 | AVG Volume (30 days): | 70.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.56 - $19.00 | Next Earning Date: | 03-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MiNK Therapeutics Inc. News
INKT Breaking Stock News: Dive into INKT Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
GlobeNewswire
10 days ago
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
GlobeNewswire
a month ago
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
GlobeNewswire
2 months ago
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Thomson Reuters StreetEvents
3 months ago
Q3 2024 Mink Therapeutics Inc Earnings Call
GuruFocus.com
3 months ago
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
GlobeNewswire
3 months ago
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
GlobeNewswire
3 months ago
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
Compare INKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INKT MiNK Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.